Significant findings of new long-term study of Resveratrol in Post-Menopausal Women

10 Jul 2019

Evolva (SIX: EVE) is pleased to announce that Emeritus Professor Peter Howe from the University of Newcastle, Australia will present outcomes from the recently concluded RESHAW study (Resveratrol Supporting Healthy Aging in Women) at the second Healthy Aging APAC summit, held July 9th-11th at the Hilton Singapore.

This will be followed by presentations from Dr. Wong and PhD student Jay Jay Thaung Zaw at the Alzheimer’s Association International Conference, held July 14th-18th in Los Angeles.

Significant findings of new long-term study of Resveratrol in Post-Menopausal Women

The RESHAW study is a two-year clinical trial of resveratrol in 141 post-menopausal women. Led by Dr. Howe and Dr. Rachel Wong at the University’s Clinical Nutrition Research Centre, it is the largest, longest running study of its kind with resveratrol. Supported by Australia’s National Health and Medical Research Council, the Australian Research Council and a grant from Evolva, RESHAW was designed to investigate the impact of resveratrol supplementation on cognitive performance, along with a wide range of secondary outcomes including body composition and perceptions of wellbeing, physical function and pain.

Based on prior clinical studies by the team indicating that resveratrol may benefit cardiovascular, metabolic and brain health by improving circulatory function, RESHAW is also testing whether a low daily dose of resveratrol can boost blood flow in the brain, aid glucose metabolism and reduce postmenopausal bone and muscle loss. In a crossover comparison, volunteers were randomized to take two capsules containing 75mg of Evolva’s Veri-te™ resveratrol ingredient daily or a matching placebo supplement for 12 months, followed by the alternative treatment for a further 12 months.
“Unique aspects of this trial include the low dose of resveratrol which has proven both efficacious and safe in our prior studies”, commented Dr Howe, “and the long duration of the study which enables us to detect changes in body composition, particularly bone mineral density which is a major concern for older women”.

“With such a highly credentialed research team, Evolva saw the potential for rapid translation of the anticipated health outcomes of resveratrol supplementation and it is exciting to finally see the culmination of more than two years of research,” said Sally Aaron, SVP, Health Ingredients and Marketing. “Dr. Howe’s upcoming presentation in Singapore will provide the first look at the evidence that supplementation with Veri-te™ resveratrol can be a key strategy for the design and delivery of effective supplements that support healthy aging."

“Our team’s dedication to the RESHAW study is now coming to fruition with the results pointing to multiple positive impacts of resveratrol for counteracting the development and progression of chronic diseases afflicting our aging Western population,” said Dr. Howe. “This bioactive polyphenol can be considered one of the most potent vasoactive nutrients that we have studied and we are excited to be finally previewing unpublished outcomes with my presentation at the Healthy Aging summit in Singapore, followed by presentations from Dr. Wong and PhD student Jay Jay Thaung Zaw at the Alzheimer’s Conference in Los Angeles.”

Read More